Rheumatoide Arthritis – Renale Manifestationen

Die Nierenbeteiligung bei rheumatologischen Erkrankungen spielt eine große diagnostische, prognostische und therapeutische Rolle im klinischen Alltag. Bei Vaskulitiden und Kollagenosen ist die Nierenfunktion in die Standarddiagnostik miteinbezogen. Weniger bekannt ist eine Nierenbeteiligung bei der rheumatoiden Arthritis, obwohl eine solche Manifestation nicht selten ist. Die Klinik zeigt, dass neben medikamentös-toxischen Effekten auch echte renale Manifestationen vorkommen. Sekundäre Amyloidosen und Vaskulitiden sowie Glomerulonephritiden stehen hier im Vordergrund und können in Kombination mit medikamentös bedingten glomerulären und tubulointerstitiellen Schäden zu differenzialdiagnostischen Problemen führen.

In the management of rheumatologic diseases, renal involvement plays a major diagnostic, prognostic and therapeutic role in daily clinical practice. In connective tissue diseases, e. g. renal manifestations are frequently observed to affect both prognosis and therapeutic approach. Renal involvement in patients with rheumatoid arthritis is less well known, but not necessarily rare. Besides drug-induced toxic effects, own renal manifestations of this autoimmune disease can be observed. Secondary amyloidosis and vasculitis, as well as glomerulonephritis, play an important role and in combination with drug-induced glomerular and tubulo-interstitial damage, they can often lead to diagnostic and therapeutic problems.

Key words

rheumatoid arthritis - renal manifestations - connective tissue diseases

• Literatur

• 1 Carmona L, Cross M, Williams B et al. Rheumatoid arthritis. Best Pract Res Clin Rheumatol 2010; 24: 733-745
• 2 Turesson C, O'Fallon WM, Crowson CS et al. Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years. Ann Rheum Dis 2003; 62: 722-727
• 3 Boers M. Renal disorders in rheumatoid arthritis. Semin Arthritis Rheum 1990; 20: 57-68
• 4 Kobayashi H, Tada S, Fuchigami T et al. Secondary amyloidosis in patients with rheumatoid arthritis: diagnostic and prognostic value of gastroduodenal biopsy. Br J Rheumatol 1996; 35: 44-49
• 5 Ramirez G, Lambert R, Bloomer HA. Renal pathology in patients with rheumatoid arthritis. Nephron 1981; 28: 124-126
• 6 Korpela M, Mustonen J, Helin H et al. Immunological comparison of patients with rheumatoid arthritis with and without nephropathy. Ann Rheum Dis 1990; 49: 214-218
• 7 Boers M, Croonen AM, Dijkmans BA et al. Renal findings in rheumatoid arthritis: clinical aspects of 132 necropsies. Ann Rheum Dis 1987; 46: 658-863
• 8 Koivuniemi R, Paimela L, Suomalainen R. Amyloidosis is frequently undetected in patients with rheumatoid arthritis. Amyloid 2008; 15: 262-268
• 9 Nakano M, Ueno M, Nishi S et al. Analysis of renal pathology and drug history in 158 Japanese patients with rheumatoid arthritis. Clin Nephrol 1998; 50: 154-160
• 10 Sanai T, Nanishi F, Nagata M. Role of amyloidosis in determining the prognosis of dialyzed patients with rheumatoid arthritis. Rheumatol Int 2007; 27: 363-367
• 11 Westermark P. Amyloid diagnosis, subcutaneous adipose tissue, immunohistochemistry and mass spectrometry. Amyloid 2011; 18: 175-176
• 12 Westermark P, Stenqvist B. A new method for the diagnosis of systemic amyloidosis. Arch Intern Med 1973; 132: 522-523
• 13 Tornroth T, Falck HM, Wafin F et al. Renal amyloidosis in rheumatic disease: A clinicopathological correlative study. In: Glenner GG, eCosta PP, de Freitas AF, eds. Amyloid and amyloidosis. Amsterdam (The Netherlands): Excerpta Medica; 1980: 191-199
• 14 Dember LM. Amyloidosis-associated kidney disease. J Am Soc Nephrol 2006; 17: 3458-3471
• 15 Mantani N, Kogure T, Shimada Y et al. Possible relationship between AA amyloidosis and decreased complements in patients with rheumatoid arthritis. J Clin Rheumatol 2003; 9: 281-282
• 16 Elkayam O, Hawkins PN, Lachmann H et al. Rapid and complete resolution of proteinuria due to renal amyloidosis in a patient with rheumatoid arthritis treated with infliximab. Arthritis Rheum 2002; 46: 2571-2573
• 17 Ravindran J, Shenker N, Bhalla AK et al. Case report: Response in proteinuria due to AA amyloidosis but not Felty's syndrome in a patient with rheumatoid arthritis treated with TNF-alpha blockade. Rheumatology (Oxford) 2004; 43: 669-672
• 18 Nishida S, Hagihara K, Shima Y et al. Rapid improvement of AA amyloidosis with humanised anti-interleukin 6 receptor antibody treatment. Ann Rheum Dis 2009; 68: 1235-1236
• 19 Inoue D, Arima H, Kawanami C et al. Excellent therapeutic effect of tocilizumab on intenstinal amyloid a deposition to active rheumatoid arthritis. Clin Rheumatol 2010; 29: 1195-1197
• 20 Watts RA, Mooney J, Lane SE et al. Rheumatoid vasculitis: becoming extinct?. Rheumatology (Oxford) 2004; 43: 920-923
• 21 Scott DG, Bacon PA. Intravenous cyclophosphamide plus methylprednisolone in treatment of systemic rheumatoid vasculitis. Am J Med 1984; 76: 377-384
• 22 Turesson C, Matteson EL. Vasculitis in rheumatoid arthritis. Curr Opin Rheumatol 2009; 21: 35-40
• 23 Ball J. Rheumatoid arthritis and polyarteritis nodosa. Ann Rheum Dis 1954; 13: 277-290
• 24 Scott DG, Bacon PA. Intravenous cyclophosphamide plus methylprednisolone in treatment of systemic rheumatoid vasculitis. Am J Med 1984; 76: 377-384
• 25 Assmann G, Pfreundschuh M, Voswinkel J. Rituximab in patients with rheumatoid arthritis and vasculitis-associated cutaneous ulcers. Clin Exp Rheumatol 2010; 28 (Suppl. 57) 81-83
• 26 Hellmann M, Jung N, Owczarczyk K et al. Successful treatment of rheumatoid vasculitis-associated cutaneous ulcers using rituximab in two patients with rheumatoid arthritis. Rheumatology (Oxford) 2008; 47: 929-930
• 27 Puechal X, Miceli-Richard C, Mejjad O et al. Anti-tumour necrosis factor treatment in patients with refractory systemic vasculitis associated with rheumatoid arthritis. Ann Rheum Dis 2008; 67: 880-884
• 28 Helin HJ, Korpela MM, Mustonen JT, Pasternack AI. Renal biopsy findings and clinicopathologic correlations in rheumatoid arthritis. Arthritis Rheum 1995; 38: 242-247
• 29 Hordon LD, Sellars L, Morley AR et al. Haematuria in rheumatoid arthritis: an association with mesangial glomerulonephritis. Ann Rheum Dis 1984; 43: 440-443
• 30 Korpela M, Mustonen J, Teppo AM et al. Mesangial glomerulonephritis as an extra-articular manifestation of rheumatoid arthritis. Br J Rheumatol 1997; 36: 1189-1195
• 31 Vane JR. Inhibition of prostagladin synthesis as a mechanism of action for aspirin-like drugs. Nature 1971; 231: 232-235
• 32 Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med 1999; 106
• 33 Schlondorff D. Renal complications of nonsteroidal anti-inflammatory drugs. Kidney Int 1993; 44: 643-653
• 34 Rossat J, Maillard M, Nussberger J et al. Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. Clin Pharmacol Ther 1999; 66: 76-84
• 35 Catella-Lawson F, McAdam B, Morrison BW et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther 1999; 289: 735-741
• 36 Silverstein FE, Faich G, Goldstein JL et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284: 1247-1255
• 37 FDA. Arthritis Advisory Committee Meeting (Februar 2001). Im Internet: http://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b2_01_merck.pdf Stand 10.06.2014
• 38 Feutren G, Mihatsch MJ. Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases. International Kidney Biopsy Registry of Cyclosporine in Autoimmune Diseases. N Engl J Med 1992; 326: 1654-1660
• 39 Marra CA, Esdaile JM, Guh D et al. The effectiveness and toxicity of cyclosporin A in rheumatoid arthritis: longitudinal analysis of a population-based registry. Arthritis Rheum 2001; 45: 240-245
• 40 Sund S, Førre O, Berg KJ et al. Morphological and functional renal effects of long-term low-dose cyclosporin A treatment in patients with rheumatoid arthritis. Clin Nephrol 1994; 41: 33-40
• 41 The Use of Cyclosporin A in Rheumatoid Arthritis. Proceedings of an International Consensus Meeting. Buckinghamshire, United Kingdom, 19-20 July, 1992. Br J Rheumatol 1993; 32 (Suppl. 01) 1-78
• 42 van den Borne BE, Landewé RB, Goei The HS et al. Cyclosporin A therapy in rheumatoid arthritis: only strict application of the guidelines for safe use can prevent irreversible renal function loss. Rheumatology (Oxford) 1999; 38: 254-259
• 43 Travis SP, Jewell DP. Salicylates for ulcerative colitis--their mode of action. Pharmacol Ther 1994; 63: 135-161
• 44 Ransford RA, Langman MJ. Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. Gut 2002; 51: 536-539
• 45 Swierkot J, Szechiński J. Methotrexate in rheumatoid arthritis. Pharmacol Rep 2006; 58: 473-492
• 46 Widemann BC, Adamson PC. Understanding and managing methotrexate nephrotoxicity. Oncologist 2006; 11: 694-703
• 47 Kremer JM, Petrillo GF, Hamilton RA. Pharmacokinetics and renal function in patients with rheumatoid arthritis receiving a standard dose of oral weekly methotrexate: association with significant decreases in creatinine clearance and renal clearance of the drug after 6 months of therapy. J Rheumatol 1995; 22: 38-40
• 48 Karie S, Gandjbakhch F, Janus N et al. Kidney disease in RA patients: prevalence and implication on RA-related drugs management: the MATRIX study. Rheumatology (Oxford) 2008; 47: 350-354
• 49 Aronoff GR, Berns JS, Brier ME, Golper TA, Morrison G, Singer I et al. Drug Prescribing in Renal Failure: Dosing Guidelines for Adults. 4th ed. Philadelphia: American College of Physicians-American Society of Internal Medicine; 1999
• 50 Cutolo M, Capellino S, Montagna P et al. Anti-inflammatory effects of leflunomide in combination with methotrexate on co-culture of T lymphocytes and synovial macrophages from rheumatoid arthritis patients. Ann Rheum Dis 2006; 65: 728-735
• 51 Strand V, Cohen S, Schiff M et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med 1999; 159: 2542-2550
• 52 Bruyn GA, Veenstra RP, Halma C, Grond J. Anti-glomerular basement membrane antibody-associated renal failure in a patient with leflunomide-treated rheumatoid arthritis. Arthritis Rheum 2003; 48: 1164-1165
• 53 Evans SJ, Webb D, Lawson TM, Siebert S. Renal tubular acidosis associated with leflunomide. Rheumatology (Oxford) 2007; 46: 1040-1040
• 54 Kemp E, Nielsen H, Petersen LJ et al. Newer immunomodulating drugs in rheumatoid arthritis may precipitate glomerulonephritis. Clin Nephrol 2001; 55: 87-88
• 55 Doulton TW, Tucker B, Reardon J, Velasco N. Antineutrophil cytoplasmic antibody-associated necrotizing crescentic glomerulonephritis in a patient receiving treatment with etanercept for severe rheumatoid arthritis. Clin Nephrol 2004; 62: 234-238
• 56 Stokes MB, Foster K, Markowitz GS et al. Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis. Nephrol Dial Transplant 2005; 20: 1400-1406
• 57 Kaneko K, Nanki T, Hosoya T et al. Etanercept-induced necrotizing crescentic glomerulonephritis in two patients with rheumatoid arthritis. Mod Rheumatol 2010; 20: 632-636
• 58 Ashok D, Dubey S, Tomlinson I. C-ANCA positive systemic vasculitis in a patient with rheumatoid arthritis treated with infliximab. Clin Rheumatol 2008; 27: 261-264
• 59 Singh JA, Christensen R, Wells GA et al. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database Syst Rev CD 007848 2009; 4
• 60 Nishimoto N, Hashimoto J, Miyasaka N et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 2007; 66: 1162-1167
• 61 Nishimoto N, Miyasaka N, Yamamoto K et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol 2009; 19: 12-19
• 62 Jones G, Sebba A, Gu J et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 2010; 69: 88-96
• 63 Smolen JS, Beaulieu A, Rubbert-Roth A et al. OPTION Investigators. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008; 371: 987-997
• 64 Emery P, Keystone E, Tony HP et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008; 67: 1516-1523 Erratum in: Ann Rheum Dis 2009: 8 296
• 65 Genovese MC, McKay JD, Nasonov EL et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 2008; 58: 2968-2980